The IIM landscape is evolving rapidly, transforming how clinicians recognize disease, assess risk, and select treatment, but translating these advances into everyday practice remains a challenge. As biomarkers and myositis-specific autoantibodies enable increasingly precise subtype classification, clinicians need practical strategies to move beyond a one-size-fits-all approach to myositis confidently distinguish IIM subtypes key mimics, and determine when negative, incomplete, or discordant serology should prompt further diagnostic evaluation rather than premature diagnostic closure. Accurate classification must also translate into identifying patients at risk for serious complications such as interstitial lung disease (ILD), malignancy, and dysphagia. At the same time, persistent glucocorticoid exposure and a rapidly evolving treatment evidence base make it essential for clinicians to understand current steroid-sparing options, distinguish approved and investigational approaches and appropriately interpret the clinical rationale and emerging evidence for neonatal receptor (FcRn) inhibition. Education is needed to equip neurologists, neuromuscular specialists, rheumatologists, dermatologists, pulmonologists, PCPs, advanced practice providers, pharmacists, nurses, rehabilitation professionals, SLPs, and other members of the interprofessional care team with actionable strategies for earlier recognition, targeted comorbidity assessment, and personalized treatment that addresses outcomes and quality-of-life priorities that matter most to patients. In this case-based CME Outfitters Webcast, expert faculty will guide learners through real-world diagnostic and treatment decision points that translate biomarker-informed IIM classification into clinical practice, linking subtype recognition to further diagnostic evaluation, targeted comorbidity assessment, multidisciplinary care, and current and emerging steroid-sparing treatment strategies. Patient perspectives on function, treatment burden, quality of life, and personal goals will be integrated into these decisions, while investigational FcRn inhibition is considered within a fair and balanced therapeutic landscape.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Pricing
CME included with membership
| Integrative Psychiatry Certificate Program | $3,350 |
Collected from the provider’s public pages · source
Specialties served/covered
- Addiction Medicine
- Addiction Psychiatry
- Adolescent Medicine
- Allergy & Clinical Immunology
- Cardiovascular Disease
- Communication & Shared Decision-Making
- Critical Care Medicine
- Diagnostic Radiology
- Emergency Medicine
- Endocrinology, Diabetes & Metabolism
- Family Medicine
- Gastroenterology
- General & Adult Psychiatry
- General Internal Medicine
- General Operative Anesthesia
- General Otolaryngology
- General Pediatrics
- General Surgery
- Gynecologic Oncology
- Hematology
- Hospice & Palliative Medicine
- Medical Oncology
- Mood & Anxiety Disorders
- Neonatal-Perinatal Medicine
- Neurology
- Neuromuscular Medicine
- Neuroradiology
- Nuclear Medicine
- Obstetrics & Gynecology
- Ophthalmology
- Orthopaedic Surgery
- Pain Medicine
- Physical Medicine & Rehabilitation
- Practice Management & Ethics
- Primary Care Sports Medicine
- Pulmonary Disease
- Radiation Oncology
- Regional Anesthesia & Acute Pain
- Rheumatology
- Sleep Medicine
- Surgical Oncology
- Thoracic Surgery
- Urological Oncology
- Anesthesiology
- Cardio-Vascular
- Cross-Specialty
- Emergency & Critical Care
- ENT & Head Neck
- GI & Liver
- Infectious Disease
- Internal Medicine
- Medical Subspecialties
- Neurology
- Ob/Gyn
- Oncology & Hematology
- Orthopedics
- Pain & Palliative
- Pediatrics
- Primary care
- Psychiatry
- Radiology
- Rehabilitation
- Sports & Exercise Medicine
- Surgery
- Urology
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- Live
- Credit · Up to 1 credit
- MOC · Up to 1 point
- Commercial Support
-
WhenAug 5 – Dec 14, 2026
-
CME Outfitters, LLC From Biomarkers to Bedside: Translating IIM Classification into Targeted Treatment Strategies If a Save the Date, add Save the
-
Efficient CME, CME Outfitters, LLC The Anti-Amyloid Therapy Roadmap: A Self-Guided Journey to Identify and Manage Early Cognitive Impairment due to Alzheimer s Disease
-
Efficient CME, CME Outfitters, LLC From Trial to Treatment: Using Modern Evidence, Expert Insight, and Practice Simulation to Navigate the Integration of Bispecific Antibodies into the Care of Patients with Multiple Myeloma
